HLS Therapeutics Reports Annual Meeting Results

About this update from Hls Therapeutics, Inc.

[{"type":"text","content":"\n\n\n\n HLS Therapeutics Reports Annual Meeting Results\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen5{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BORDER-TOP:black 1pt; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 1pt\n}\n.prngen3{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BORDER-TOP:black 0.5pt solid; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 1pt\n}\n.prngen4{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt; BORDER-RIGHT:black 0.5pt solid; BORDER-BOTTOM:black 0.5pt solid; BORDER-LEFT:black 0.5pt solid\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prncbts{\nBORDER-TOP:black 0.5pt solid\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnbrbrs{\nBORDER-RIGHT:black 0.5pt solid\n}\n.prnbbbs{\nBORDER-BOTTOM:black 0.5pt solid\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE; BORDER-TOP:1pt black; BORDER-RIGHT:1pt black; BORDER-BOTTOM:1pt black; BORDER-LEFT:1pt black\n}\n.prnpr2{\nPADDING-RIGHT:0.17em\n}\n.prnbsbls{\nBORDER-LEFT:black 0.5pt solid\n}\n.prnpl2{\nPADDING-LEFT:0.17em\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n TORONTO\n \n\n ,\n \n\n June 20, 2025\n \n\n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces voting results from its Annual Meeting of Shareholders held in a virtual format on\n \n June 20\n \n , 2025.\n \n\n A total of 16,073,335 Common Shares, or 50.81% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:\n \n\n\n\n\n\n\n\n\n\n\n\n Name of Nominee\n \n\n\n\n\n\n\n\n Votes Cast\n \n\n\n\n\n\n FOR\n \n\n\n\n\n\n\n\n % of Vote Cast\n \n\n\n\n\n\n FOR\n \n\n\n\n\n\n\n\n Votes\n \n\n\n\n\n\n WITHHELD\n \n\n\n\n\n\n\n\n % o...

More updates from Hls Therapeutics, Inc.